Research and clinical trials

an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...

This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...

Many people with Crohn's also have obesity or diabetes and may be prescribed GLP-1 drugs. Understanding safety, symptom overlap, and current research helps you and your care team make informed choices about starting or...

New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...

This study suggests a targeted phage can reduce inflammation driven by Crohn’s‑associated E. coli without wiping out the gut microbiome, and it may boost the effect of lower steroid doses. That could eventually mean...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Crohn's disease, and Irritable bowel syndrome. The original article is from msn.com.

This study quantifies the large NHS and societal costs of Crohn’s disease and ulcerative colitis in the UK and highlights that ongoing management and maintaining remission are major drivers of expense.

This study suggests a new, targeted way to reduce gut inflammation by disabling harmful E. coli behaviors linked to Crohn's disease without wiping out the microbiome.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. Open the original article for...

If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...

Genetic studies help reveal biological pathways behind Crohn’s disease, which can guide research into new treatments and better understanding of disease mechanisms. People with Crohn’s disease may find it useful to know...

The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...

Fibrostenotic Crohn’s disease causes strictures and often requires surgery; emerging anti‑fibrotic therapies aim to prevent or slow structural bowel damage beyond inflammation control. Patients and clinicians may see new...

Cure8 could only read part of this source from law360.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Access, cost, and policy.

Cure8 found this source from iovs.arvojournals.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...

This study suggests a biological link between NOD2 gene dysfunction and estrogen signaling that could help explain why Crohn’s disease is more common in females and point to a new, hormone-related pathway to investigate...

Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...

This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...

This trial targets fibrotic narrowings (strictures) in Crohn’s disease — a common complication without approved drug treatments — so positive results could change care options and reduce the need for surgery.

Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Many people with Crohn’s and IBD turn to Instagram Reels for information. This study found that a lot of that content is only moderate in quality and some contains clinically significant misinformation, which could...

This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings...

This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...

Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Research and clinical trials. Open the original article for the full details.

This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...

Many people with Crohn’s look to short social videos for information. Moderate-quality and misleading reels could influence treatment decisions, emotional wellbeing, and when people seek medical care.

People with Crohn’s disease often seek information and support on social media; this study shows Instagram Reels vary in quality and medical-advice videos may include misinformation. That matters because inaccurate...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

A reliable, accurate intestinal ultrasound could make routine monitoring easier, faster, and less costly than repeated MRI for people with Crohn’s disease. The study shows strong agreement between ultrasound scores and...

There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.

Researchers mapped cell-type gene activity in Crohn’s ileum and found persistent immune-related gene activation in stem cells after inflammation healed, plus macrophage signatures tied to the JAK/STAT pathway. This could...

This study links an HLA gene (DRB1) to shared T cell receptor patterns in both Crohn’s disease and ulcerative colitis, suggesting common immune targets across IBD subtypes. That could help researchers identify antigens...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Investigational or...

The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...

This study maps gene activity in over a million gut cells and finds lasting molecular changes in stem cells after inflammation, which could help explain recurrence and guide future research toward new drug targets.

People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.

A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...

Based on the title and source metadata, this appears to be an event or fundraiser related to Inflammatory bowel disease and Community and awareness. The original article is from msn.com.

This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from uk.style.yahoo.com.

This trial shows darvadstrocel did not outperform placebo for complex perianal Crohn’s fistulas, so it does not support changing care now. High healing rates after surgical curettage and closure suggest the surgical step...

Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for...

This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...

Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if...

Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...

Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Stricture. The original article is from quiverquant.com.

This describes an investigational drug approach (PALI-2108) aimed at intestinal fibrosis, a key issue in fibrostenotic Crohn’s disease for which there are no approved antifibrotic therapies. Patients and clinicians may...